KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR

Area of Science:

• Molecular Biology
• Genetics
• Biochemistry

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
• The most common CFTR mutation, F508del, leads to protein misfolding, premature degradation, and impaired chloride transport.
• Post-translational modifications (PTMs) of CFTR, like methylation and ubiquitination, influence its stability and function.

Purpose of the Study:

• To investigate the role of demethylases in the stability of the F508del-CFTR mutant.
• To identify specific demethylases whose inhibition can restore F508del-CFTR function.
• To explore therapeutic strategies targeting CFTR PTMs for cystic fibrosis treatment.

Main Methods:

• Utilized a siRNA library targeting all human demethylases.
• Assessed the impact of demethylase downregulation on F508del-CFTR stability and channel function.
• Evaluated the combined effect of demethylase inhibition and CFTR correctors.

Main Results:

• Downregulation of KDM2A and KDM3B significantly increased the stability of F508del-CFTR.
• Inhibition of KDM2A and KDM3B enhanced the functional rescue of F508del-CFTR by CFTR correctors.
• These findings suggest a competition between methylation and ubiquitination in regulating CFTR degradation.

Conclusions:

• Targeting KDM2A and KDM3B represents a promising therapeutic strategy for cystic fibrosis.
• Modulating CFTR PTMs, specifically favoring methylation over ubiquitination, can restore protein function.
• This approach offers a potential pathway to treat CF patients with the F508del mutation.